Navigation Links
Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics
Date:7/22/2008

Latest awards under Therapeutics Development Initiative bring MJFF's current active industry collaborations to 23; next deadline January 20, 2009

NEW YORK, July 22 /PRNewswire-USNewswire/ -- As part of its mission to speed delivery of transformative treatments and a cure for Parkinson's disease, The Michael J. Fox Foundation for Parkinson's Research has awarded $2.7 million in total funding to six industry research teams. The awards were granted under MJFF's Therapeutics Development Initiative (TDI) program. Open exclusively to researchers at biotech and pharmaceutical companies, TDI is the cornerstone of the Foundation's venture philanthropy efforts to spark and expand industry investment in PD drug development. In an increasingly risk-averse research funding climate, TDI helps to push promising candidate therapeutics forward in industry pipelines by allowing the Foundation to share the risk of drug development.

"At MJFF, our job is to do whatever it takes to speed therapeutics development for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation. "Early on we realized the critical importance of forging financial and intellectual partnerships with industry as well as academic research teams. Our private philanthropy dollars -- raised largely from patients themselves -- have a critical role to play in 'de-risking' therapeutic targets for industry investment in order to keep the most promising ideas moving forward toward clinical testing and pharmacy shelves."

Funded projects focus on:

-- Developing a vaccine that could protect against toxicity of the PD-implicated protein alpha-synuclein (Ingeborg Muehldorfer, Ph.D., Rentschler Biotechnologie, Laupheim, Germany);

-- Improving delivery of the gold-standard Parkinson's treatment, levodopa, which could lessen debilitating side effects of the drug including dyskinesias, the uncontrollable movements that arise with long-term levodopa therapy (Verne Cowles, P
'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
2. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
3. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
6. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
7. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
8. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
9. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
10. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
11. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 11 Phosphagenics,Limited ("Phosphagenics") (ASX: POH; AIM: PSG; ... their joint phase 2 human clinical,trial to establish ... of metabolic syndrome is advancing at three sites ... of study participants, the,double-blind phase 2 trial, which ...
... Feb. 11 ,Pharmion (Nasdaq: PHRM ) and ... Medicines Agency (EMEA) and the European Commission (EC),designated ... Orphan,Medicinal Product for the treatment of acute myelogenous ... require that the product be,intended for the treatment ...
Cached Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... entitled " Lovetraction Lines ." It's for women interested in improving their love ... desire. The course, which officially launched to the public early this morning, has ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association ... and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to ... will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality provider of ... announced that the Centers for Medicare and Medicaid (CMS) have awarded its agency the ... 24/7 Care At Home’s agency is one of three top Orange County agencies to ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... Western ... success of the 2015 Special Olympics World Games, the largest sports and humanitarian event ... the 1984 Olympic Games. , The World Games, held July 25 through August 2, ...
Breaking Medicine News(10 mins):Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3
... oral cancer, which a dentist could perform by simply using ... set to be developed by researchers at the University of ... The international research team, involving scientists in Sheffield, has been ... to develop the test, which could provide an accurate diagnosis ...
... available in French . Inhibiting prostate cancer ... governs tumour growth A kinase is a type of ... proteins required for cell growth and maintenance, and researchers have ... developing prostate cancer. "It,s known as Mnk, and although it ...
... College of Nursing has been awarded a $753,817 grant ... Health Resources and Services Administration (HRSA), to prepare advanced ... high quality healthcare in rural and medically underserved urban ... to i-LEAD, Innovation in Leadership and Administration in Nursing ...
... Comprehensive Cancer Center and the departments of Chemistry ... uncovered a role for an essential cell protein ... "power plant" of the cell. The import ... for the replication, transcription and translation of the ...
... is twofold, as the patients not only suffer from ... called phantom pain. Unlike bodily wounds which will eventually ... a lifetime. "Phantom pain is very difficult to treat", ... "Mostly they prove to be highly therapy-resistant", the Professor ...
... , THURSDAY, Aug. 5 (HealthDay News) -- While maintaining ... of heart disease and diabetes, being overweight may actually ... researchers say. This new finding suggests that overweight ... open-angle glaucoma (POAG), one of the most common age-related ...
Cached Medicine News:Health News:New 'dentist' test to detect oral cancer will save lives 2Health News:New 'dentist' test to detect oral cancer will save lives 3Health News:Inhibiting prostate cancer without disturbing regular body processes 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 3Health News:UCLA researchers discover protein that shuttles RNA into cell mitochondria 2Health News:UCLA researchers discover protein that shuttles RNA into cell mitochondria 3Health News:Prosthesis with information at its fingertips 2Health News:Excess Weight May Protect Women From Type of Glaucoma 2Health News:Excess Weight May Protect Women From Type of Glaucoma 3
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: